| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/INFDIS/128.1.7 |
| P698 | PubMed publication ID | 4198027 |
| P50 | author | Scott B Halstead | Q60059357 |
| P2093 | author name string | Casals J | |
| Shotwell H | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pathogenesis | Q372016 |
| Dengue virus | Q476209 | ||
| P304 | page(s) | 7-14 | |
| P577 | publication date | 1973-07-01 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | Studies on the pathogenesis of dengue infection in monkeys. I. Clinical laboratory responses to primary infection | |
| P478 | volume | 128 |
| Q40546528 | A Blunted Blood Plasmacytoid Dendritic Cell Response to an Acute Systemic Viral Infection Is Associated with Increased Disease Severity |
| Q28483765 | A genetic and pathologic study of a DENV2 clinical isolate capable of inducing encephalitis and hematological disturbances in immunocompetent mice |
| Q40329672 | A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness |
| Q24276108 | A lethal murine infection model for dengue virus 3 in AG129 mice deficient in type I and II interferon receptors leads to systemic disease |
| Q28473775 | A non mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice |
| Q35272502 | An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques |
| Q34999885 | Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases |
| Q38647063 | Animal models for dengue vaccine development and testing. |
| Q37987131 | Animal models of dengue virus infection |
| Q39678175 | Antibody-dependent enhancement of dengue virus infection in vitro by undiluted sera from monkeys infected with heterotypic dengue virus |
| Q42991886 | Barriers to preclinical investigations of anti-dengue immunity and dengue pathogenesis |
| Q39357324 | Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric yellow fever 17D/dengue viruses |
| Q26825708 | Can non-human primates serve as models for investigating dengue disease pathogenesis? |
| Q55021139 | Characterization of recent and minimally passaged Brazilian dengue viruses inducing robust infection in rhesus macaques. |
| Q34389377 | Chemically induced temperature-sensitive mutants of dengue virus type 2: comparison of temperature sensitivity in vitro with infectivity suckling mice, hamsters, and rhesus monkeys |
| Q35758626 | Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies |
| Q40130106 | Could an experimental dengue virus infection fail to induce solid immunity against homologous viral challenge in non-human primates? |
| Q27480760 | Demonstration of binding of dengue virus envelope protein to target cells |
| Q24550739 | Dengue and dengue hemorrhagic fever |
| Q38614539 | Dengue epidemiology and pathogenesis: images of the future viewed through a mirror of the past. |
| Q33340800 | Dengue in New Caledonia. Study of 68 pediatric cases |
| Q28542607 | Dengue therapeutics, chemoprophylaxis, and allied tools: state of the art and future directions |
| Q34367194 | Dengue vaccines: recent developments, ongoing challenges and current candidates |
| Q21142740 | Dengue virus infection and virus-specific HLA-A2 restricted immune responses in humanized NOD-scid IL2rgammanull mice |
| Q52725492 | Dengue viruses cleave STING in humans but not in nonhuman primates, their presumed natural reservoir. |
| Q38201151 | Developing a dengue vaccine: progress and future challenges |
| Q34259867 | Differential in vivo clearance and response to secondary heterologous infections by H2(b)-restricted dengue virus-specific CD8+ T cells |
| Q35031833 | Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques |
| Q26864533 | Fever versus fever: the role of host and vector susceptibility and interspecific competition in shaping the current and future distributions of the sylvatic cycles of dengue virus and yellow fever virus |
| Q55519030 | Flavivirus serocomplex cross-reactive immunity is protective by activating heterologous memory CD4 T cells. |
| Q36730637 | Genetic and phenotypic characterization of sylvatic dengue virus type 2 strains |
| Q56766779 | Global spread of epidemic dengue: the influence of environmental change |
| Q37336440 | High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection |
| Q40883572 | Immunological sensitization following inapparent infection with dengue virus type 3 in rhesus monkeys |
| Q35613349 | Immunology and immunopathogenesis of dengue disease |
| Q51733262 | Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4. |
| Q36454058 | In vitro virulence marker: growth of dengue-2 virus in human leukocyte suspension cultures |
| Q34281507 | Infection dynamics of sylvatic dengue virus in a natural primate host, the African Green Monkey |
| Q40528042 | Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity |
| Q35942502 | Models of dengue virus infection |
| Q27480391 | Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge |
| Q37213365 | Mouse models of dengue virus infection and disease |
| Q24276139 | Mouse models of dengue virus infection for vaccine testing |
| Q27010151 | Mouse models to study dengue virus immunology and pathogenesis |
| Q29618172 | Neutralization and antibody-dependent enhancement of dengue viruses |
| Q36718596 | Potential of ancestral sylvatic dengue-2 viruses to re-emerge |
| Q27485489 | Primary and Secondary Infections of Macaca fascicularis Monkeys with Asian and American Genotypes of Dengue Virus 2 |
| Q40037808 | Prior Exposure to Zika Virus Significantly Enhances Peak Dengue-2 Viremia in Rhesus Macaques |
| Q40822336 | Quantity of dengue virus required to infect rhesus monkeys |
| Q27472702 | Randomized, Placebo-Controlled Trial of Nonpegylated and Pegylated Forms of Recombinant Human Alpha Interferon 2a for Suppression of Dengue Virus Viremia in Rhesus Monkeys |
| Q34058747 | Report of an NIAID workshop on dengue animal models |
| Q26860307 | Role of microparticles in dengue virus infection and its impact on medical intervention strategies |
| Q91728039 | Route of inoculation and mosquito vector exposure modulate dengue virus replication kinetics and immune responses in rhesus macaques |
| Q37372592 | Serotype-specific host responses in rhesus macaques after primary dengue challenge |
| Q40863361 | Studies on dengue 2 virus infection in cyclophosphamide-treated rhesus monkeys |
| Q34500910 | Synchrony of sylvatic dengue isolations: a multi-host, multi-vector SIR model of dengue virus transmission in Senegal |
| Q36450864 | Testing of novel dengue virus 2 vaccines in African green monkeys: safety, immunogenicity, and efficacy |
| Q40172034 | The haemostatic defect in viral haemorrhagic fevers |
| Q34903764 | The history and evolution of human dengue emergence |
| Q33676847 | The role of the mosquito in a dengue human infection model |
| Q34607919 | Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected]. |
| Q27480996 | Transcriptional Activation of Interferon-Stimulated Genes but Not of Cytokine Genes after Primary Infection of Rhesus Macaques with Dengue Virus Type 1 |
| Q38540058 | Trials and tribulations on the path to developing a dengue vaccine |
| Q34238916 | Utility, limitations, and future of non-human primates for dengue research and vaccine development |
| Q37330748 | Vaccine-induced enhancement of viral infections. |
| Q36082908 | Viral kinetics of primary dengue virus infection in non-human primates: a systematic review and individual pooled analysis |
| Q40381397 | Viremia and antibody response in green monkeys (Chlorocebus aethiops sabaeus) infected with dengue virus type 2: a potential model for vaccine testing |
| Q40378824 | Viremia and the magnitude of the immune response upon infection of green monkeys with dengue virus type 2 are strain-dependent |
| Q39011713 | Wild dengue virus types 1, 2 and 3 viremia in rhesus monkeys |
| Q33850577 | Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus |
Search more.